Identification of a Structurally Distinct CD101 Molecule Encoded in the 950-kb Idd10 Region of NOD Mice

  1. Carlos Penha-Gonçalves1*,
  2. Carolyn Moule1*,
  3. Luc J. Smink1,
  4. Joanna Howson1,
  5. Simon Gregory2,
  6. Jane Rogers2,
  7. Paul A. Lyons1,
  8. Joseph J. Suttie1,
  9. Christopher J. Lord1,
  10. Laurence B. Peterson3,
  11. John A. Todd1 and
  12. Linda S. Wicker, 1
  1. 1Juvenile Diabetes Research Foundation/Wellcome Trust (JDRF/WT) Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, Addenbrooke’s Hospital, Cambridge, U.K
  2. 2The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, U.K
  3. 3Department of Pharmacology, Merck Research Laboratories, Rahway, New Jersey

    Abstract

    Genes affecting autoimmune type 1 diabetes susceptibility in the nonobese diabetic (NOD) mouse (Idd loci) have been mapped using a congenic strain breeding strategy. In the present study, we used a combination of BAC clone contig construction, polymorphism analysis of DNA from congenic strains, and sequence mining of the human orthologous region to generate an integrated map of the Idd10 region on mouse chromosome 3. We found seven genes and one pseudogene in the 950-kb Idd10 region. Although all seven genes in the interval are Idd10 candidates, we suggest the gene encoding the EWI immunoglobulin subfamily member EWI-101 (Cd101) as the most likely Idd10 candidate because of the previously reported immune-associated properties of the human CD101 molecule. Additional support for the candidacy of Cd101 is the presence of 17 exonic single-neucleotide polymorphisms that differ between the NOD and B6 sequences, 10 causing amino acid substitutions in the predicted CD101 protein. Four of these 10 substitutions are nonconservative, 2 of which could potentially alter N-linked glycosylation. Considering our results together with those previous reports that antibodies recognizing human CD101 modulate human T-cell and dendritic cell function, there is now justification to test whether the alteration of CD101 function affects autoimmune islet destruction.

    Footnotes

    • Address correspondence and reprint requests to Dr. Linda S Wicker, JDRF/WT Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Addenbrooke’s Hospital, Cambridge, CB2 2XY, U.K. E-mail: linda.wicker{at}cimr.cam.ac.uk.

      Received for publication 9 August 2002 and accepted in revised form 5 March 2003.

      C.J.L. is currently affiliated with the Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, U.K.

      BAC, bacterial artificial chromosome; DC, dendritic cell; IEL, intraepithelial lymphocyte; FPC, fingerprint contig; MHC, major histocompatibility complex; SNP, single nucleotide polymorphism; STS, sequence-tagged site.

    • *

      * C.P.-G. and C.M. contributed equally to this work.

    « Previous | Next Article »Table of Contents